- Advancing Inclusive Research: Despite greater attention to the topic of increasing representation of communities of color in clinical research over the last decade, few significant advances have been made. In 1997, 92% of participants in clinical trials targeting cancer, central nervous system diseases, and heart disease were White; by 2015, White patients still compromised 85% of participants. For patients of color, significant barriers persist, including lack of access to quality care and clinical trial options, social and financial burdens, and lack of awareness and trust in clinical research. To address these disparities, research organizations require greater leadership commitment and accountability to diversity, equity, and inclusion; support for hiring, training, and mentoring diverse faculty and staff; strengthening community engagement and patient support; and re-evaluating study design practices. Genentech’s grantmaking priorities to advance inclusive research are focused on pioneering, testing, and scaling sustainable approaches to addressing patient barriers and institutional needs.
- Promoting Equity in Care: Racial and ethnic disparities in health access and healthcare outcomes are tied to a range of factors, such as social determinants of health, including access and coverage for high quality care, the accumulated effects of trauma, bias and discrimination, as well as unequal treatment within the healthcare system. Across the therapeutic areas in which Genentech is active, racial and ethnic disparities abound. Black men are more likely to die from prostate cancer than White men. Black and Native American communities experience the highest prevalence of asthma, and Black children die at a rate that is five times higher than White children. Recent studies have demonstrated a higher incidence of multiple sclerosis (MS) in Black patients in comparison to other racial and ethnic groups, and the progression of the disease is more aggressive in Black patients than in White patients.
- Funded projects typically span 12-24 months
- Start date must be January 1, 2021 or later
- Grants cannot be self-renewing
- Strong proposals will demonstrate the rigor behind the project, potential to translate findings into actionable change, fill gaps in the evidence base, replicate and lead to lasting systems change
- Clear evaluation, research and/or dissemination strategy associated with the proposal, so that learnings can be shared and scaled with other groups/sectors
- Partnership, including resource allocation, with communities and organizations who understand and are affected by health disparities, where appropriate
- Proposals reflecting a particularly innovative approach or out-of-the box thinking are strongly encouraged
- Organizational commitment to anti-racism and application of values of justice, equity, diversity, and inclusion into practice
For more information, visit https://bit.ly/308Qktx